Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 1;32(1):61-66.
doi: 10.1097/MOH.0000000000000849. Epub 2024 Nov 25.

HCT in the widening spectrum of congenital immunodeficiencies

Rafaella Muratori  1 , Carmem Bonfim  2
Affiliations
Review

HCT in the widening spectrum of congenital immunodeficiencies

Rafaella Muratori et al. Curr Opin Hematol. .

Abstract

Purpose of review: Hematopoietic stem cell transplantation (HSCT) and inborn errors of immunity (IEI) have been closely linked since transplantation was first used to cure severe combined immunodeficiency (SCID) in 1968. Since then, novel genes and diseases have been continually added to the ongoing list of IEI, and new data on indications and outcomes have emerged. We review recent data and progress in the field of hematopoietic cell transplantation (HCT) for IEI including new diseases and complications.

Recent findings: Emerging data from haploidentical transplants, newborn screening results, and multicentric studies reveals promising outcomes for IEI. Immune dysregulation diseases deserve special attention regarding disease control and may require additional drugs pretransplant. Female carriers of X-linked Chronic granulomatous may present with a severe phenotype warranting the need for HCT. Insights from infectious complications and long-term comorbidities should help guide decisions to treat IEI patients.

Summary: From classical indications to recently described diseases, HCT for immunodeficiencies is a rapidly growing field. Novel data regarding alternative donor transplants, results from large cohorts, and long-term complications provide valuable knowledge for clinical practice.

PubMed Disclaimer

References

    1. Bousfiha A, Moundir A, Tangye SG, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol 2022; 42:1508–1520.
    1. Lum SH, Albert MH, Gilbert P, et al. Outcomes of HLA-mismatched HCT with TCRαβ/CD19 depletion or post-HCT cyclophosphamide for inborn errors of immunity. Blood. Published online April 26, 2024.
    1. AlSaedi H, Mohammed R, Siddiqui K, et al. HLA-haploidentical donor transplants with posttransplant cyclophosphamide in children with primary immune deficiency disorders. Bone Marrow Transplant 2022; 57:668–670.
    1. Thakar MS, Logan BR, Puck JM, et al. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. Lancet 2023; 402:129–140.
    1. Lankester AC, Neven B, Mahlaoui N, et al. Hematopoietic cell transplantation in severe combined immunodeficiency: the SCETIDE 2006-2014 European cohort. J Allergy Clin Immunol 2022; 149:1744.e8–1754.e8.

MeSH terms